Search

Jonathan Zalevsky

from Orinda, CA
Age ~50
Get Report
Also known as:
Jan Zalevsky, Jonathan Zalensky, Jonathan Y, Jonathon Y
Phone and address:
34 Oak Ridge Ln, Orinda, CA 94563
Related to:
Elianna James, 73Gregory Zalevsky, 87Lilly Zalevsky, 78Robert J DefeaBetty M Defea, 93Kathryn Defea, 61Margarita A Yelevich, 54
Connected to:
David M Zalevsky, 56Svetlana I Zalevskaya, 49Linda Zalewitz, 75Ashley N Zalewski, 39Bartlomiej Zalewski, 58Dale M Zalewski, 62Danny Zalewski, 51Dianne M Zalewski, 77Edward F Zalewski, 57Frederick A Zalewski, 57

Jonathan Zalevsky Phones & Addresses

  • 34 Oak Ridge Ln, Orinda, CA 94563
  • 20743 Hillsdale Rd, Riverside, CA 92508 (951) 656-9376
  • 2829 Montecito Dr, Fallbrook, CA 92028
  • San Francisco, CA
  • Pasadena, MD
  • Menlo Park, CA
  • Redwood City, CA
  • Mountain View, CA
  • San Diego, CA
  • Boulder, CO

Work

Company: Nektar therapeutics Jul 2015 Position: Chief research and development officer

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of California, San Francisco 1995 to 2002 Specialities: Philosophy

Skills

Immunology • Research

Industries

Pharmaceuticals

Resumes

Resumes

Jonathan Zalevsky Photo 1

Chief Research And Development Officer

View page
Location:
20743 Hillsdale Rd, Riverside, CA 92508
Industry:
Pharmaceuticals
Work:
Nektar Therapeutics
Chief Research and Development Officer
Takeda California
Head Immunology Research
Education:
University of California, San Francisco 1995 - 2002
Doctorates, Doctor of Philosophy, Philosophy University of Colorado Boulder
Skills:
Immunology
Research

Publications

Us Patents

Protein Based Tnf-Α Variants For The Treatment Of Tnf-Α Related Disorders

View page
US Patent:
7446174, Nov 4, 2008
Filed:
Apr 14, 2005
Appl. No.:
11/108001
Inventors:
John R. Desjarlais - Pasadena CA, US
Paul Michael Steed - Chapel Hill NC, US
Jonathan Zalevsky - Riverside CA, US
David Edmund Szymkowski - Monrovia CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
C07K 17/00
G01N 33/53
US Classification:
530351, 435 695, 435 71, 435335
Abstract:
The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders.

Bmp-7 Variants With Improved Properties

View page
US Patent:
7459527, Dec 2, 2008
Filed:
Mar 31, 2005
Appl. No.:
11/097960
Inventors:
John R. Desjarlais - Pasadena CA, US
Shannon Alicia Marshall - San Francisco CA, US
Jonathan Zalevsky - Riverside CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
C07K 14/00
C07K 14/52
C12N 15/00
US Classification:
530350, 530351, 435 691, 435 695
Abstract:
The invention relates to variants of BMP-7 with improved properties and methods for their use.

Methods For Rational Pegylation Of Proteins

View page
US Patent:
7587286, Sep 8, 2009
Filed:
Mar 31, 2004
Appl. No.:
10/820466
Inventors:
John Rudolph Desjarlais - Pasadena CA, US
Jonathan Zalevsky - Riverside CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
G06F 19/00
US Classification:
702 27
Abstract:
The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Globular Adiponectin Variants

View page
US Patent:
7592423, Sep 22, 2009
Filed:
May 30, 2006
Appl. No.:
11/421055
Inventors:
Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
C07K 14/00
C07K 1/00
C07K 17/00
C07K 16/00
A61K 38/24
A61K 38/27
US Classification:
530350, 530395, 530397, 530399
Abstract:
An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

Methods For Rational Pegylation Of Proteins

View page
US Patent:
7610156, Oct 27, 2009
Filed:
Sep 30, 2004
Appl. No.:
10/956352
Inventors:
John R. Desjarlais - Pasadena CA, US
Jonathan Zalevsky - Riverside CA, US
Gregory L. Moore - Pasadena CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
G06F 19/00
US Classification:
702 27
Abstract:
The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Pegylated Tnf-Α Variant Proteins

View page
US Patent:
7642340, Jan 5, 2010
Filed:
Aug 8, 2005
Appl. No.:
11/200444
Inventors:
John R. Desjarlais - Pasadena CA, US
Jonathan Zalevsky - Riverside CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
A61K 38/17
A61K 38/19
C07K 14/52
US Classification:
530350, 424 851, 530351
Abstract:
The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.

Pharmaceutical Compositions For The Treatment Of Tnf-Α Related Disorders

View page
US Patent:
7662367, Feb 16, 2010
Filed:
Jun 22, 2006
Appl. No.:
11/472864
Inventors:
John R. Desjarlais - Pasadena CA, US
Paul Michael Steed - Chapel Hill NC, US
Jonathan Zalevsky - Riverside CA, US
David Edmund Szymkowski - Monrovia CA, US
David F. Carmichael - Monrovia CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
A61K 38/19
A61K 38/00
C07K 38/00
US Classification:
424 851, 514 2, 530350
Abstract:
The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α a buffer and a tonicity agent wherein said composition has a pH from approximately 5. 0 to 8.

Pharmaceutical Compositions Of Adiponectin Variants And Methods Of Storage

View page
US Patent:
7678886, Mar 16, 2010
Filed:
May 30, 2006
Appl. No.:
11/421061
Inventors:
Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US
Assignee:
Xencor, Inc. - Monrovia CA
International Classification:
C07K 14/00
C07K 1/00
C07K 17/00
C07K 16/00
A61K 38/24
A61K 38/27
US Classification:
530350, 530395, 530397, 530399
Abstract:
A composition comprising an adiponectin variant at a concentration of at least 2. 0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4 C. for one week in 10 mM PO, 150 mM NaCl buffer.
Control profile
Jonathan Zalevsky from Orinda, CA, age ~50 Get Report